In a nutshell This study aimed to investigate the effectiveness of cabazitaxel used for patients with metastatic castration-resistant prostate cancer. This study found that patients treated with cabazitaxel had maintained or improved quality of life and pain control. Some background One treatment option for prostate cancer is androgen deprivation...
Read MoreCurrent disease status-First occurrence of the cancer Posts on Medivizor
Looking for patients with triple negative breast cancer to test atezolizumab
In a nutshell This trial is examining the effectiveness of chemotherapy and atezolizumab (Tecentriq), given before surgery, for triple negative breast cancer. The main outcomes to be measured will be response in the breast tissue and lymph nodes and survival. The details Triple negative breast cancer is not dependent on the HER2 receptors or...
Read MoreComparing daily versus weekly imaging checks in radiation therapy for prostate cancer
In a nutshell This study aimed to investigate the best timing of treatment verification imaging used in radiation therapy for patients with prostate cancer. This study found that patients undergoing daily imaging had less risk of their cancer returning and had reduced rectal side-effects. Some background One main treatment option for prostate cancer...
Read MoreOlaparib and abiraterone for metastatic castration-resistant prostate cancer
In a nutshell This study aimed to evaluate the use of abiraterone (Zytiga) and olaparib (Lynparza) in advanced prostate cancer. This study concluded that olaparib in combination with abiraterone provided clinical benefit for patients with metastatic castration-resistant prostate cancer compared with abiraterone alone. Some background...
Read MoreShould men with castration-resistant metastatic prostate cancer receive further hormone therapy?
In a nutshell This study aimed to discover the optimal timing of hormone therapies in combination with androgen-deprivation therapy (ADT) for patients with metastatic hormone-sensitive prostate cancer. This study found that treatment with a second hormone therapy after prostate cancer becomes immune to hormone treatment is associated...
Read MoreSide-effects and quality of life changes after robotic prostate surgery
In a nutshell This study aimed to evaluate short and medium-term patient-reported side-effects after robotic prostate surgery. This study found that patient-reported outcome measures evaluating urinary symptoms and health related quality of life do not significantly change after robotic prostate surgery. Some background...
Read MoreCombining antiangiogenic drugs and chemotherapy to treat advanced NSCLC
In a nutshell This study looked at a combination of chemotherapy and an antiangiogenic drug bevacizumab to treat patients with advanced non-small-cell lung cancer. The authors concluded that this combination may have potential to control cancer in these patients. Some background Despite the major advances in cancer treatments in recent years,...
Read MoreEverolimus and exemstane for treatment of HR+/HER2- advanced or metastatic breast cancer
In a nutshell This study looked at the effectiveness and safety of a combination of two cancer drugs, everolimus (Afinitor) and exemestane (Aromasin), in women after menopause with advanced breast cancer. The authors found that these drugs were safe and effective in the treatment of these women. Some background Breast cancer is...
Read MoreCombining therapies to treat advanced NSCLC
In a nutshell This trial examined the effectiveness of combining the targeted therapy drug pembrolizumab (Keytruda) with chemotherapy at treating certain types of advanced non-small-cell lung cancer. The trial concluded that this combination is more beneficial than chemotherapy alone for treating this subset of patients. Some background PD-1...
Read MoreOxaliplatin based treatments as adjuvant chemotherapy treatment in colon cancer patients
In a nutshell This study investigated the effectiveness of a 3-month oxaliplatin-based chemotherapy treatment after surgery in patients with stage 3 colon cancer. Researchers suggested 6-months of treatment is associated with better outcomes. Some background The current standard treatment for stage 3 colon cancer patients is surgery followed by...
Read MoreNew melanoma therapies are associated with improved survival rates
In a nutshell This study examined the survival rates of melanoma patients with brain metastasis treated with new therapies. Researchers concluded that PD-1 agents are associated with improved survival outcomes. Some background More than 50% of melanoma patients develop brain metastasis (cancer spread), with an overall survival of 17 to 22 weeks....
Read MoreEncorafenib plus binimetinib to treat inoperable advanced melanoma
In a nutshell This study examined the effectiveness of encorafenib (Braftovi) alone or in combination with binimetinib or vemurafenib (Zelboraf) alone in BRAF-mutant melanomas. Researchers suggested that the combined treatment showed improved cancer outcomes with manageable side effects. Some background Some melanoma patients have a...
Read More